Charles Stewart
Radiation Oncology · Tulsa, OKNPI 1043243884
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,250 of the $2,666 with a category attached, or 84.4%. Novocure Inc. accounts for 84.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $2,250 and has fallen 88.4% since, to $262 in 2025.
Across 22 payments — averaging $121.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$2K
- Daiichi Sankyo Inc.$163
- Novartis$100
- Pfizer$76
- Bayer$28
- AVEO Pharmaceuticals, Inc.$15
- plus $34 from 3 others
What the payments were for
- Consulting fees$2,25084%
- Food & beverage$41616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 1 | $2,250 |
| Daiichi Sankyo Inc. | 10 | $163 |
| Novartis | 5 | $100 |
| Pfizer | 1 | $76 |
| Bayer | 1 | $28 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Beone Medicines USA, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Intuitive Surgical | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$2,250
How this compares
$2,666 in reported general payments places this provider in the 70th percentile of 43 radiation oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pentoxifylline | 76 | $2,231 |
| Gabapentin | 25 | $993 |
| Dexamethasone | 16 | $633 |
| Pantoprazole Sodium | 25 | $230 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Tulsa
- Diane HeatonTulsa$36K
- Mykhanh NguyenTulsa$15K
- Nathan UyTulsa$5K
- Terry StylesTulsa$642
- Frederick WillisonTulsa$414
- Stephen SackTulsa$373
- Ralph JensenTulsa$67
- William GoadTulsa$48
- Jerry JaboinOklahoma City$14K
- Walter WattsMuskogee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.